DocDollars

Astellas Pharma Global Development

IL · United States · Reporting entity ID 100000005406

Total reported 2019–2025
$88.8M
#106 of 2,960 reporting companies — 0.1% of all reported industry payments
$3.06M in general payments across 3,010 records, plus $85.7M in research funding across 16,738 records.

How it breaks down

General payments $3,060,688
Research funding $85,693,417

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Astellas Pharma Global Development reported $88.8M to US doctors and teaching hospitals from 2019 to 2025, ranking #106 of 2,960 reporting companies. 97% of that was research funding and 3% general payments such as consulting, speaking, food and travel. 3,010 general payment records and 16,738 research records were filed.

Common questions about Astellas Pharma Global Development

How much has Astellas Pharma Global Development paid US doctors?

Astellas Pharma Global Development reported $88,754,104 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $3,060,688 in general payments, $85,693,417 in research funding.

How does Astellas Pharma Global Development rank among drug and device companies?

It ranks #106 of 2,960 reporting entities by total reported value, about 0.1% of all industry payments in the dataset.

Does a payment from Astellas Pharma Global Development mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.